Nationwide Children's News Releases
Viewing: 51-60 of 99 | All
Mar 20, 2014
Parent Project Muscular Dystrophy Awards Nationwide Childrens Hospital; Names Hospital Certified Duchenne Care Center
Nationwide Children’s Hospital was named the first Certified Duchenne Care Center by Parent Project Muscular Dystrophy (PPMD), the leading advocacy organization working to end Duchenne muscular dystrophy (Duchenne).
Dec 03, 2013
Dr. Edwin Horwitz Appointed Director of Blood and Marrow Transplant at Nationwide Childrens Hospital
Edwin M. Horwitz, MD, PhD, recently was appointed director of Blood and Marrow Transplant (BMT) at Nationwide Children’s Hospital. Dr. Horwitz, board-certified in Pediatric Hematology/Oncology, comes to Nationwide Children’s from the Children’s Hospital of Philadelphia (CHOP).
Nov 25, 2013
Two Faculty in The Research Institute at Nationwide Childrens Hospital Named AAAS Fellows
Brian K. Kaspar, PhD, and Veronica J. Vieland, PhD, principal investigators in The Research Institute at Nationwide Children’s Hospital, have been named Fellows of the American Association for the Advancement of Science (AAAS).
Oct 30, 2013
Study: Researchers Identify Way to Increase Gene Therapy Success
Scientists in The Research Institute at Nationwide Children’s Hospital have found a way to overcome one of the biggest obstacles to using viruses to deliver therapeutic genes: how to keep the immune system from neutralizing the virus before it can deliver its genetic payload.
Oct 18, 2013
AveXis- BioLife Licenses Spinal Muscular Atrophy (SMA) Patent Portfolio from Nationwide Childrens Hospital and The Ohio State University
BioLife, a synthetic biology platform company soon to be renamed AveXis, has been granted exclusive rights to the spinal muscular atrophy gene therapy program developed at The Research Institute at Nationwide Children’s Hospital and The Ohio State University in Columbus, Ohio.
Oct 17, 2013
AveXis and BioLife Announce The Research Institute at Nationwide Childrens Hospital Received Fast Track Status for Spinal Muscular Atrophy Treatment
AveXis and BioLife, synthetic biology platform companies, today announced that The Research Institute at Nationwide Children’s Hospital received Fast Track designation from the U.S.
Oct 08, 2013
$25.4 Million Awarded to Center for Clinical and Translational Science to Continue Critical Bench to Bedside Translational Research
The National Institutes of Health has awarded a $25.4 million grant to the Center for Clinical and Translational Science (CCTS), a collaboration between The Ohio State University and Nationwide Children’s Hospital created to accelerate basic science discoveries into life-saving medical
Sep 09, 2013
Therapy Slows Onset and Progression of Lou Gehrigs Disease, Study Finds
Studies of a therapy designed to treat amyotrophic lateral sclerosis (ALS) suggest that the treatment dramatically slows onset and progression of the deadly disease, one of the most common neuromuscular disorders in the world.
Aug 09, 2013
Combined Therapy Could Repair and Prevent Damage in Duchenne Muscular Dystrophy
New research on two promising gene therapies suggests that combining them into one treatment not only repairs muscle damage caused by Duchenne muscular dystrophy, but also prevents future injury from the muscle-wasting disease.
Aug 08, 2013
New Drug Improves Walking Performance for Duchenne Muscular Dystrophy Patients
Results from a clinical trial of eteplirsen, a drug designed to treat Duchenne muscular dystrophy, suggest that the therapy allows participants to walk farther than people treated with placebo and dramatically increases production of a protein vital to muscle growth and health.